SCHEMBL18805813

SCHEMBL18805813

CCC1OC(C)C(NC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ CYP3A4 P08684 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ CA9 Q16790 6/20 0.35
▸ CA1 P00915 5/20 0.35
▸ CA2 P00918 5/20 0.35
▸ CA12 O43570 4/20 0.35
▸ NR3C1 P04150 1/20 0.35
▸ FYN P06241 1/20 0.35
▸ ADRA2A P08913 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ ADRA2B P18089 1/20 0.35
▸ DRD4 P21917 1/20 0.35
▸ DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15763314 1.00 LMNA (0.42) LMNAKMT2AALDH1A1POLBCYP3A4
SCHEMBL24453808 0.87 LMNA (0.41) LMNAKMT2AALDH1A1POLBCYP3A4
SCHEMBL18102369 0.85 LMNA (0.57) LMNAKMT2AALDH1A1POLBCYP3A4
SCHEMBL25480951 0.85 LMNA (0.57) LMNAKMT2AALDH1A1POLBCYP3A4
SCHEMBL21366081 0.85 LMNA (0.57) LMNAKMT2AALDH1A1POLBCYP3A4
SCHEMBL24378476 0.85 LMNA (0.57) LMNAKMT2AALDH1A1POLBCYP3A4
SCHEMBL23626630 0.85 LMNA (0.57) LMNAKMT2AALDH1A1POLBCYP3A4
SCHEMBL14010273 0.85 LMNA (0.57) LMNAKMT2AALDH1A1POLBCYP3A4
SCHEMBL16392612 0.85 LMNA (0.57) LMNAKMT2AALDH1A1POLBCYP3A4
SCHEMBL16392625 0.85 LMNA (0.57) LMNAKMT2AALDH1A1POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10001487-B2 Glucose derivative, and cell imaging method and imaging agent using said derivative HIROSAKI UNIVERSITY (JP) 2018-06-19 — — US disclosed
US-20170122955-A1 NOVEL GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE HIROSAKI UNIVERSITY (JP) 2017-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170122955-A1 NOVEL GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE SLC2A4, SLC2A1, UGGT1 LMNA 1224/4885KMT2A 3704/4885ALDH1A1 494/4885
US-10001487-B2 Glucose derivative, and cell imaging method and imaging agent using said derivative SLC2A4, SLC2A1, G6PD LMNA 976/4885KMT2A 3818/4885ALDH1A1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback